In December 2018, Aligos entered into an agreement with Luxna Biotech Co., Ltd. whereby Aligos acquired from Luxna an exclusive license to innovative modified nucleic acid technology coming out of Professor Satosh Obika’s lab at Osaka University targeting multiple genes in specific diseases.
In July 2020, Aligos entered into a collaboration and license agreement with KU Leuven, in particular its Centre for Drug Design and Discovery (CD3), and the Rega Institute for Medical Research, to develop a coronavirus protease inhibitor as a potential therapeutic candidate to address the COVID-19 pandemic (caused by SARS-CoV-2 infection) and other potential zoonotic coronavirus infections. Professor Johan Neyts, Ph.D. is the principal investigator at KU Leuven.
In June 2018, Aligos entered into an agreement with Emory University whereby Aligos acquired from Emory a license to technology with respect to a novel class of non-nucleoside class-II capsid assembly modulators. The underlying technology licensed by Aligos was invented and developed at Emory in the laboratory of Raymond Schinazi, PhD, DSc, FAASLD (Pediatrics) by Dr. Schinazi and his team including Sebastien Boucle, PhD (Pediatrics), Franck Amblard, PhD (Pediatrics), Ozkan Sari, PhD (Pediatrics) and Leda Bassit, PhD (Pediatrics).